COVAX | SSGSX | COVAX / SSGSX | |
Total Expense Ratio | N/A | N/A | - |
Annual Report Gross Expense Ratio | N/A | N/A | - |
Fund Existence | 23 years | 26 years | - |
Gain YTD | -10.440 | 1.761 | -593% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 2000 | 2500 | 80% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 985M | 6.85B | 14% |
Annual Yield % from dividends | 1.26 | 0.35 | 356% |
Returns for 1 year | -8.77 | 1.76 | -499% |
Returns for 3 years | -18.22 | -1.81 | 1,007% |
Returns for 5 years | -0.22 | 7.99 | -3% |
Returns for 10 years | -12.99 | 17.10 | -76% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
PYVAX | 19.30 | N/A | N/A |
Payden Equity Income Adviser | |||
VALLX | 39.77 | -0.29 | -0.72% |
Value Line Larger Companies Focused Inv | |||
RIRGX | 71.17 | -1.59 | -2.19% |
American Funds Capital Income Bldr R6 | |||
DUSLX | 38.27 | -1.00 | -2.55% |
DFA US Large Cap Growth Instl | |||
APGRX | 19.83 | -0.74 | -3.60% |
Yorktown Growth Institutional |